Merck KGaA Confirms Late-Stage Discussions With Springworks Therapeutics On Potential Acquisition
April 25 (Reuters) - Merck KGaA MRCG.DE:
EQS-ADHOC: MERCK KGAA: MERCK CONFIRMS LATE-STAGE DISCUSSIONS WITH SPRINGWORKS THERAPEUTICS, INC. ON POTENTIAL ACQUISITION
MERCK KGAA: PARTIES ARE IN DISCUSSION ON BASIS OF A PRICE OF AROUND USD 47 PER SHARE
MERCK KGAA: NO FINAL DECISION HAS BEEN TAKEN AND NO LEGALLY BINDING AGREEMENT HAS BEEN ENTERED INTO
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Big Tech’s AI Data Center Power Demands Trigger $15B PJM Auction and a Nuclear SMR Boom

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey







